



Psoriasis Enrollment Form

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

<b>PATIENT INFORMATION</b>	Patient Name: _____	<b>PRESCRIBER INFORMATION</b>	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

**INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)**

<b>CLINICAL</b>	Need By Date: _____ Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other: _____																														
	Date of Diagnosis: _____ Diagnosis: <input type="checkbox"/> L40.0 Psoriasis Vulgaris <input type="checkbox"/> L40.59 Psoriatic Arthritis <input type="checkbox"/> New diagnosis <input type="checkbox"/> Other _____																														
	<table border="1"> <tr> <th>Prior Therapies</th> <th>Medication</th> <th>Reason for Discontinuation</th> <th>Prior Therapies</th> <th>Medication</th> <th>Reason for Discontinuation</th> </tr> <tr> <td><input type="checkbox"/> Biologics</td> <td>_____</td> <td>_____</td> <td><input type="checkbox"/> UVB</td> <td>_____</td> <td>_____</td> </tr> <tr> <td><input type="checkbox"/> Methotrexate</td> <td>_____</td> <td>_____</td> <td><input type="checkbox"/> Topical</td> <td>_____</td> <td>_____</td> </tr> <tr> <td><input type="checkbox"/> Oral Meds</td> <td>_____</td> <td>_____</td> <td><input type="checkbox"/> Other</td> <td>_____</td> <td>_____</td> </tr> <tr> <td><input type="checkbox"/> PUVA</td> <td>_____</td> <td>_____</td> <td></td> <td></td> <td></td> </tr> </table>	Prior Therapies	Medication	Reason for Discontinuation	Prior Therapies	Medication	Reason for Discontinuation	<input type="checkbox"/> Biologics	_____	_____	<input type="checkbox"/> UVB	_____	_____	<input type="checkbox"/> Methotrexate	_____	_____	<input type="checkbox"/> Topical	_____	_____	<input type="checkbox"/> Oral Meds	_____	_____	<input type="checkbox"/> Other	_____	_____	<input type="checkbox"/> PUVA	_____	_____			
	Prior Therapies	Medication	Reason for Discontinuation	Prior Therapies	Medication	Reason for Discontinuation																									
	<input type="checkbox"/> Biologics	_____	_____	<input type="checkbox"/> UVB	_____	_____																									
	<input type="checkbox"/> Methotrexate	_____	_____	<input type="checkbox"/> Topical	_____	_____																									
	<input type="checkbox"/> Oral Meds	_____	_____	<input type="checkbox"/> Other	_____	_____																									
	<input type="checkbox"/> PUVA	_____	_____																												
Current Medications: _____ Is the patient also taking methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No																															
Allergies: _____ Does the patient have a latex allergy? <input type="checkbox"/> Yes <input type="checkbox"/> No																															
Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No																															
BSA affected by Psoriasis _____%																															
Has patient had positive TB test? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, date of last chest x-ray: _____																															

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> Cimzia®	<b>Starter Dose</b> <input type="checkbox"/> Starter Kit (200mg/mL Prefilled Syringes)	<input type="checkbox"/> Inject 400mg SC at weeks 0, 2, and 4	<input type="checkbox"/> 1 Kit = 6 x 200 mg/mL PFS	0
	<b>Maintenance Dose</b> <input type="checkbox"/> 200mg/mL Prefilled Syringe	<input type="checkbox"/> Inject 400mg SC every 2 weeks <input type="checkbox"/> Inject 400mg SC every 4 weeks <input type="checkbox"/> Inject 200mg SC every 2 weeks	<input type="checkbox"/> 1 Carton = 2 x 200 mg/mL PFS	_____
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 150mg/mL Prefilled Syringe <input type="checkbox"/> 150mg/mL Sensoready Pen	<input type="checkbox"/> Psoriasis Initiation Dose: Inject 300mg SC Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29	<input type="checkbox"/> 8 Pens/PFS	0
		<input type="checkbox"/> Psoriasis Maintenance Dose: Inject 300mg SC starting Day 29 & then every 4 weeks thereafter	<input type="checkbox"/> 2 Pens/PFS	_____
		<input type="checkbox"/> Psoriatic Arthritis Initiation Dose: Inject 150mg SC Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29	<input type="checkbox"/> 4 Pens/PFS	0
		<input type="checkbox"/> Psoriatic Arthritis Maintenance Dose: Inject the contents of 150mg SC starting Day 29 & then every 4 weeks thereafter	<input type="checkbox"/> 2 Pens/PFS	_____
<input type="checkbox"/> Enbrel®	<input type="checkbox"/> 50mg/mL Sureclick™ <input type="checkbox"/> 50mg/mL Prefilled Syringe <input type="checkbox"/> 50mg/mL Mini Cartridge <input type="checkbox"/> 25mg/0.5mL Prefilled Syringe <input type="checkbox"/> 25mg Multiple-dose Vial <input type="checkbox"/> 25mg/0.5mL Single-dose Vial	<input type="checkbox"/> Psoriasis Induction Dose: Inject 50mg SC TWICE a week (3-4 days apart) for 3 months, then maintenance dosing	_____	_____
		<input type="checkbox"/> Psoriasis Maintenance Dose: Inject 50mg SC ONCE a week	_____	_____
		<input type="checkbox"/> Psoriatic Arthritis Dose: Inject 50mg SC ONCE a week	_____	_____
		<input type="checkbox"/> Other: _____	_____	_____

X	X
PRODUCT SUBSTITUTION PERMITTED Ancillary supplies and kits will be provided as needed for administration.	(Date) _____ DISPENSE AS WRITTEN _____ (Date) _____

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 1449 (4/21)



**Psoriasis Enrollment Form**

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

PRESCRIPTION INFORMATION

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> Humira®	<b>Starter Dose</b> <input type="checkbox"/> 40mg/0.8mL Pen Psoriasis Starter (4 pens)	<input type="checkbox"/> Inject 80mg SC day 1, 40mg Day 8, then 40mg every 14 days thereafter <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Kit	0
	<b>Maintenance Dose</b> <input type="checkbox"/> 40mg/0.8mL Pen <input type="checkbox"/> 40mg/0.8mL Prefilled Syringe <input type="checkbox"/> 20mg/0.4mL Prefilled Syringe <input type="checkbox"/> 10mg/0.2mL Prefilled Syringe	<input type="checkbox"/> Inject 40mg SC every OTHER week <input type="checkbox"/> Inject 40mg SC every week <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 Pens/PFS <input type="checkbox"/> 4 Pens/PFS	_____
<input type="checkbox"/> Humira® (Citrate-free)	<b>Starter Dose</b> <input type="checkbox"/> 80mg/0.8mL and 40 mg/0.4mL Pen Psoriasis Starter (3 pens) <input type="checkbox"/> 40mg/0.4mL Pen Psoriasis Starter (4 pens)	<input type="checkbox"/> Inject 80mg SC day 1, 40mg Day 8, then 40mg every 14 days thereafter <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Kit	0
	<b>Maintenance Dose</b> <input type="checkbox"/> 40mg/0.4mL CF Pen <input type="checkbox"/> 40mg/0.4mL CF Prefilled Syringe <input type="checkbox"/> 20mg/0.2mL CF Prefilled Syringe <input type="checkbox"/> 10mg/0.1mL CF Prefilled Syringe	<input type="checkbox"/> Inject 40mg SC every OTHER week <input type="checkbox"/> Inject 40mg SC every week <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 Pens/PFS <input type="checkbox"/> 4 Pens/PFS	_____
<input type="checkbox"/> Ilumya®	<input type="checkbox"/> 100mg/mL Prefilled Syringe	<input type="checkbox"/> Initiation Dose: Inject 100mg SC at weeks 0 and 4, then every 12 weeks thereafter	<input type="checkbox"/> 1 PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject 100mg SC every 12 weeks	<input type="checkbox"/> 1 PFS	_____
<input type="checkbox"/> Otezla	<input type="checkbox"/> Otezla Starter Pack <input type="checkbox"/> Otezla 30mg Tablet	<input type="checkbox"/> Initiation Dose: Take as directed per package instructions	<input type="checkbox"/> 1 Starter Kit (55 tablets)	0
		<input type="checkbox"/> Maintenance Dose: Take 1 tablet by mouth twice daily	<input type="checkbox"/> 60 Tablets	_____
<input type="checkbox"/> Remicade®	<input type="checkbox"/> Remicade 100mg vial	<input type="checkbox"/> Induction: Infuse _____mg IV at weeks 0, 2, and 6 <input type="checkbox"/> Maintenance: Infuse _____mg IV at every 8 weeks	<input type="checkbox"/> _____ # Vial(s)	_____
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 50mg/0.5mL SmartJect™ <input type="checkbox"/> 50mg/0.5mL Syringe	<input type="checkbox"/> Inject 1 dose (50mg) SC once monthly	<input type="checkbox"/> 1 Pen/PFS	_____
		<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Skyrizi®	<input type="checkbox"/> 75mg/0.83mL Prefilled Syringe	<input type="checkbox"/> Initiation Dose: Inject 150mg (two 75mg syringes) SC at week 0 and 4, followed by every 12 weeks thereafter	<input type="checkbox"/> 2 PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject 150mg (two 75mg syringes) SC every 12 weeks	<input type="checkbox"/> 2 PFS	_____
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45mg/0.5mL Prefilled Syringe <input type="checkbox"/> 45mg/0.5mL Single-dose Vial <input type="checkbox"/> 90mg/1mL Prefilled Syringe	<input type="checkbox"/> Initiation Dose: Inject 1 prefilled syringe SC Day 1	<input type="checkbox"/> 1 PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject the contents of 1 prefilled syringe SC starting Day 29 & every 12 weeks thereafter	<input type="checkbox"/> 1 PFS	_____
		<input type="checkbox"/> Other: _____	_____	
<input type="checkbox"/> Taltz®	<input type="checkbox"/> 80mg/mL Prefilled Syringe <input type="checkbox"/> 80mg/mL Pen	<input type="checkbox"/> Psoriasis Initiation Dose: Inject 160mg SC week 0, followed by 80mg week 2, 4, 6, 8, 10, 12 and then every 4 weeks thereafter	<input type="checkbox"/> 8 Pens/PFS	0
		<input type="checkbox"/> Psoriatic Arthritis Initiation Dose: Inject 160mg SC week 0, and then 80mg every 4 weeks	<input type="checkbox"/> 2 Pens/PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject 80mg SC every 4 weeks <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Pen/PFS	_____
<input type="checkbox"/> Tremfya®	<input type="checkbox"/> 100mg/mL Prefilled Syringe <input type="checkbox"/> 100mg/mL One-Press Injector	<input type="checkbox"/> Initiation Dose: Inject 100mg SC week 0, week 4, and then every 8 weeks thereafter	<input type="checkbox"/> 1 Pen/PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject 100mg SC every 8 weeks	<input type="checkbox"/> 1 Pen/PFS	_____

X

X

PRODUCT SUBSTITUTION PERMITTED (Date) \_\_\_\_\_  
Ancillary supplies and kits will be provided as needed for administration.

DISPENSE AS WRITTEN (Date) \_\_\_\_\_

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 1449 (4/21)